The global healthcare technology (HealthTech) and medical technology (MedTech) mergers and acquisitions ecosystem in August 2026 operates under a regime defined by institutional market participants as "HealthTech 2.0" or "Industrial Maturity". Moving past the venture subsidised capital deployment of the post-pandemic era and the severe valuation compression experienced during 2022–2023, current market mechanics demonstrate disciplined capital allocation, rigorous underwriting

The global healthcare technology (HealthTech) mergers and acquisitions (M&A) ecosystem at mid-year 2026 has entered a period described by corporate development executives and private equity sponsors as "HealthTech 2.0" or "Industrial Maturity". Moving decisively beyond the venture-subsidised experimentation of the early 2020s and the severe valuation recalibrations of 2022–2023, the current transaction environment demonstrates strong capital deployment alongside target select